

Annual General Meeting Fresenius SE & Co. KGaA




May 13, 2016

Another year of strong sales and earnings growth


	Sales	EBIT	Net income
FY 2015	€27,626 m	€3,958 m	€1,423 m
Growth constant currency	9%	13%	21%
Growth actual rates	19%	25%	31%

23rd consecutive dividend increase




12th consecutive record year

Sales (in €bn)



Net income (in €m)



Stability through quality



Stability through our decentralized structure



Global presence, local roots

Stability through growing demand



Stability through four strong business segments



Fresenius Medical Care: Making dialysis accessible to millions of patients



Fresenius Kabi: Improving production technology for higher quality



Fresenius Helios: Developing digital healthcare solutions




Fresenius Vamed: Linking the project and service businesses




Strong and stable growth without major acquisitions

Fresenius Group sales




Fresenius outperforms DAX index

Total Return 2005 - 2015




Total Return 2015



A steadily growing Fresenius workforce

223,704

Employees worldwide



2016: An outstanding start to the new business year

	Sales	EBIT	Net income
Q1 2016	€6,914 m	€959 m	€362 m
Growth constant currency	7%	11%	23%
Growth actual rates	7%	13%	24%

2016 financial guidance

Sales growth
constant currency

6% - 8%

Net income growth
constant currency

8% - 12%

New mid-term financial goals

2019:

€36 - €40 bn in sales


€2.0 - €2.25 bn in net income

- At comparable exchange rates
 - Without large acquisitions
-

Continued strong growth expected

Within a 5-year period

Within a 10-year period



Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Annual General Meeting Fresenius SE & Co. KGaA



May 13, 2016
